WebAug 31, 2024 · BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2024. ... Ongoing PROTECT phase 3 study met its interim primary endpoint at 49.8% ... WebNov 4, 2024 · Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, …

BION-1301 Chinook Therapeutics

WebNov 4, 2024 · These data reinforce our confidence in the dose and schedule we have selected to take forward in the phase 3 trial of BION-1301 for patients with IgAN that we plan to initiate next year.” WebNov 4, 2024 · Data was presented from Cohort 1 in Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and initial clinical responses of open-label BION-1301 treatment in patients with IgAN. Patients in Cohort 1 received an ... how much money does dababy have 2022

2024-11-04 NDAQ:KDNY Press Release - stockhouse

WebMay 3, 2024 · Parts 1 and 2 of the Phase 1/2 study (NCT03945318) assessing single and multiple ascending doses of BION-1301 in HV are complete. Part 3 is an ongoing, open-label, multicohort design in patients with IgAN treated with BION-1301 for up to 1 year. WebBION-1301 Publications. Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy ISN World Congress of Nephrology 2024 March 2024. A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA … Web2 days ago · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. … how do i quote an author